We are live on ! Find out more
CASI

CASI Pharmaceuticals
CASI

Delisted

CASI was delisted on the 25th of February, 2026.

Back to rankings

35 hedge funds and large institutions have $6.05M invested in CASI Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

250% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 2

17% more funds holding

Funds holding: 30 → 35 (+5)

7% more capital invested

Capital invested by funds: $5.66M → $6.05M (+$385K)

Holders
35
Holders Change
+5
Holders Change %
+16.67%
% of All Funds
1.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
7
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WSCM
Wellington Shields Capital Management
New York
+$94.6K
2
WJA
Williams Jones & Associates
New York
+$80.4K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$55.8K
4
MHP
Manatuck Hill Partners
Connecticut
+$28.5K
5
Citadel Advisors
Citadel Advisors
Florida
+$24.2K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$425K
2
VKH
Virtu KCG Holdings
New York
-$8.97K
3
TRCT
Tower Research Capital (TRC)
New York
-$8K

CASI Hedge Fund Activity: Q1 2014 in Review

35 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q1 2014, worth a combined $6.05M — up 6.8% from $5.66M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new CASI positions and 1 closed out — a net gain of 5 holders — while 7 added to existing stakes and 2 trimmed.

The largest buyer was Wellington Shields Capital Management, adding an estimated $94.6K. The largest seller was Sabby Management, cutting an estimated $425K.

  • 35 institutional investors held CASI Pharmaceuticals (CASI) as of Q1 2014, up from 30 in Q4 2013.
  • Funds reported $6.05M of CASI Pharmaceuticals stock for Q1 2014, up 6.8% quarter-over-quarter.
  • 6 funds opened new CASI Pharmaceuticals positions in Q1 2014 and 1 closed out, a net change of +5 holders.
  • The largest CASI Pharmaceuticals buyer in Q1 2014 was Wellington Shields Capital Management, an estimated $94.6K added.
  • The largest CASI Pharmaceuticals seller in Q1 2014 was Sabby Management, an estimated $425K sold.

Based on aggregated 13F filings for Q1 2014.